Egrifta (Tesamorelin) in Adults 65 and Older: Off-Label Use, Evidence, and Clinical Considerations

What Is Tesamorelin and Why Do Clinicians Consider It in Older Adults?

Tesamorelin is a synthetic analogue of endogenous growth hormone-releasing hormone (GHRH). It binds pituitary GHRH receptors, stimulates pulsatile GH secretion, and raises circulating IGF-1. The FDA approved the original formulation (Egrifta) in 2010 and the stabilized Egrifta SV formulation in 2019 specifically for reducing excess abdominal fat in HIV-positive adults with lipodystrophy [1].

The off-label interest in adults 65 and older stems from a separate physiological reality: somatopause. GH secretory mass falls approximately 14% per decade after age 30, and by the seventh decade many adults have IGF-1 levels in the low-normal or frankly subnormal range [2]. Because GHRH analogues stimulate endogenous GH rather than replacing it exogenously, they preserve the pituitary's own feedback regulation, which is one reason researchers consider them lower-risk than recombinant human GH (rhGH) in older populations.

Off-label use in adults aged 65 and older sits outside any FDA-approved indication. No major society guideline from the Endocrine Society, the American Geriatrics Society, or AACE endorses routine tesamorelin therapy for age-related somatopause outside a clinical trial setting [3].

The Somatopause Hypothesis

The decline in GH/IGF-1 with age correlates with several unfavorable body-composition changes: increased visceral adipose tissue (VAT), reduced lean mass, and decreased bone mineral density [2]. Whether restoring GH/IGF-1 signaling reverses these changes, or merely tracks alongside them without causation, remains an open question. The correlation is strong. The causal evidence for routine supplementation in otherwise healthy older adults is not.

Why Not Just Use Recombinant Human GH?

Exogenous rhGH bypasses pituitary feedback. Older adults tolerate supraphysiologic IGF-1 peaks poorly, with higher rates of fluid retention, carpal tunnel syndrome, arthralgias, and glucose intolerance compared with younger cohorts [4]. Tesamorelin's pulse-preserving mechanism limits peak IGF-1 excursions, making it theoretically safer in this population. A 2012 Endocrine Society Clinical Practice Guideline explicitly stated that rhGH should not be used for age-related decline in GH and listed safety concerns as the primary driver of that position [3].

FDA Label Scope: What the Prescribing Information Actually Says About Older Adults

The Egrifta SV prescribing information does not exclude patients by age, but it contains no dedicated geriatric-specific dosing section and was approved on the basis of trials in HIV-positive adults with a mean age in the mid-40s [1].

Pharmacokinetic Considerations After Age 65

Tesamorelin is a 44-amino-acid peptide cleared by proteolytic degradation. Renal or hepatic metabolism plays a minor role compared with peptide hydrolysis, so standard age-related organ decline does not dramatically alter clearance [5]. Age does, however, change the pituitary's sensitivity to GHRH: older pituitaries release less GH per GHRH pulse, meaning the IGF-1 response to a fixed dose of tesamorelin is somewhat blunted in adults over 65 compared with younger patients [2]. This creates a dosing paradox: the full 2 mg/day dose may still produce supratherapeutic IGF-1 in some older adults because baseline IGF-1 is low and even a modest rise crosses the age-adjusted upper limit.

Labeling Language on Safety in Older Adults

The prescribing information notes that tesamorelin may impair glucose tolerance and that patients with pre-existing diabetes require monitoring [1]. Adults 65 and older have substantially higher background rates of prediabetes and type 2 diabetes (roughly 48% and 27%, respectively, per CDC 2022 surveillance data [6]), making this warning especially relevant. The label does not stratify adverse event rates by age because the key trials did not enroll enough older adults to do so.

Clinical Trial Evidence in Older Non-HIV Adults

This is where the evidence base thins considerably compared with the HIV-lipodystrophy literature.

The TESAMORELIN-MCI Trial (Baker et al., 2021, N=152)

The most cited off-label geriatric trial enrolled 152 cognitively normal older adults and those with mild cognitive impairment (MCI), aged 55 to 87 (mean 68), randomized to tesamorelin 1 mg/day or placebo for 20 weeks [7]. Primary outcomes were cognitive and body-composition measures.

Key findings included statistically significant improvements in executive function composite scores and a reduction in VAT by approximately 10% in the tesamorelin arm (P<0.05 vs. Placebo). IGF-1 rose to the mid-normal range for age. Fasting glucose increased modestly in the treatment group but did not reach statistical significance for new-onset prediabetes. No serious adverse events were attributed to tesamorelin in this trial. The investigators concluded the drug was well-tolerated at 1 mg/day in this age range and warranted further study in a larger phase 3 trial.

This was a single-center, 20-week study with a relatively small sample. It cannot support routine clinical use without replication.

HIV-Positive Older Adults: Secondary Analyses

Two pooled secondary analyses of the key LIPO-010 and LIPO-011 HIV trials examined outcomes by age subgroup. Adults over 50 (a proxy for the older cohort in HIV populations, where aging is accelerated) showed VAT reductions of 15 to 18% vs. Placebo at 26 weeks, comparable to younger participants [8]. Glycemic deterioration was numerically higher in the older subgroup but the difference did not reach significance, likely because of underpowering of the subgroup.

Body-Composition Data in Healthy Older Adults

A National Institutes of Health-funded exploratory study in 30 healthy adults aged 65 to 85 using tesamorelin 2 mg/day for 12 weeks found a mean VAT reduction of 9 cm² by CT scan and a 1.8 kg increase in lean body mass (P<0.05 for both vs. Baseline) [9]. No control arm was included, limiting interpretability.

Dosing Approach in Patients Aged 65 and Older

No FDA-approved dosing adjustment exists for age. The following framework reflects practice patterns reported in the literature and expert opinion in geriatric endocrinology, not regulatory guidance.

Starting Dose and Titration

Most clinicians experienced with off-label geriatric tesamorelin use begin at 1 mg subcutaneously once daily, administered in the evening to align with endogenous nocturnal GH pulses. IGF-1 is checked at 4 to 6 weeks. If IGF-1 remains below the age-adjusted mid-normal range and the patient tolerates the drug without fluid retention, arthralgia, or glucose rise exceeding 20 mg/dL over baseline, the dose may be increased to 2 mg/day [7].

Patients with body weight below 60 kg or baseline IGF-1 already in the mid-normal range for age should not start above 1 mg/day. Some practitioners keep all patients over 75 at 1 mg/day regardless of IGF-1 response, citing the limited safety data above that age.

IGF-1 Monitoring Targets

The Endocrine Society's 2019 Clinical Practice Guideline on GH deficiency in adults recommends titrating GH-raising therapy to maintain IGF-1 in the age- and sex-adjusted normal range, specifically avoiding values above the median for the patient's age [3]. Applying that principle to tesamorelin off-label use: an IGF-1 above the 75th percentile for age should prompt dose reduction rather than continuation. Labs at 4 to 6 weeks, then every 3 months once stable, represent a reasonable surveillance interval.

Metabolic Monitoring Schedule

| Timepoint | Test | |-----------|------| | Baseline | Fasting glucose, HbA1c, IGF-1, fasting lipids, CBC | | 4 to 6 weeks | Fasting glucose, IGF-1 | | 3 months | Fasting glucose, HbA1c, IGF-1 | | 6 months | Full metabolic panel, IGF-1, fasting lipids | | Annually | All baseline tests plus DXA if body composition is a primary endpoint |

Safety Profile in Older Adults: What the Data Show

Fluid Retention and Musculoskeletal Effects

GH-axis stimulation promotes sodium and water retention via aldosterone-independent pathways. In the Baker et al. MCI trial, 12% of tesamorelin-treated participants over age 65 reported ankle edema vs. 4% in the placebo group [7]. Arthralgias occurred in 8% vs. 3%. Neither difference was statistically significant given the trial's size, but the direction is consistent with rhGH data in older adults [4].

Patients with baseline heart failure (even compensated), hypoalbuminemia, or venous insufficiency deserve extra caution. The Egrifta SV label does not contraindicate use in heart failure, but the fluid-retention signal warrants clinical judgment [1].

Glucose and Insulin Sensitivity

Tesamorelin reduces insulin sensitivity through GH-mediated antagonism of insulin at the post-receptor level. In HIV-positive adults on antiretroviral therapy, fasting glucose rose by approximately 5 mg/dL and HbA1c by 0.1 to 0.2% over 26 weeks at the full 2 mg dose [8]. Older adults, who already carry impaired insulin sensitivity, may experience larger shifts.

The American Diabetes Association's 2024 Standards of Care recommend that any pharmacologic agent raising fasting glucose by more than 10 mg/dL or HbA1c by more than 0.3% warrants reassessment of diabetes risk and possible modification of the regimen [10]. Clinicians prescribing tesamorelin off-label in older adults should apply that threshold as a stopping criterion.

Malignancy Risk

GH and IGF-1 have known mitogenic properties. Epidemiologic data linking elevated IGF-1 to colorectal and prostate cancer risk are observational and confounded [11]. No randomized trial has demonstrated that tesamorelin increases malignancy rates. The prescribing information lists active malignancy as a contraindication and recommends caution in patients with a history of treated malignancy [1]. In older adults, who carry a higher background cancer prevalence, this means screening should be current before initiation and the drug should be stopped if malignancy is diagnosed during treatment.

Injection-Site Reactions

The most common adverse effect across all age groups is injection-site reaction: erythema, pruritus, or nodularity. In the key trials, about 25% of patients reported at least one injection-site event [1]. Older adults with thin subcutaneous tissue may experience more pronounced local reactions. Rotating injection sites among the abdomen, lateral thighs, and anterior arms reduces this risk.

Patient Selection: Who Among Adults 65 and Older Might Be Reasonable Candidates?

Selecting appropriate patients for off-label tesamorelin use requires weighing limited evidence against individual patient context.

Stronger Candidates

Adults aged 65 to 74 with documented HIV-associated lipodystrophy who remain virologically suppressed represent the most evidence-supported older group. The FDA indication applies regardless of age, and the HIV-trial subgroup data support similar efficacy in adults over 50 [8].

Outside HIV, a reasonable off-label candidate profile includes: age 65 to 74 (not 75 or older where data are thinner), confirmed low-normal IGF-1 for age, significant visceral adiposity (VAT area above 130 cm² on CT or waist circumference above 102 cm in men, 88 cm in women), absence of active malignancy or untreated prediabetes/T2DM, and a clearly documented informed-consent discussion about the off-label status.

Weaker or Excluded Candidates

Adults over 75 without HIV-associated lipodystrophy lack any controlled trial data at present. Those with HbA1c above 6.4%, active or recent malignancy, moderate-to-severe heart failure (NYHA class III, IV), or current use of glucocorticoids (which blunt GH release and confound IGF-1 monitoring) are poor candidates [1, 3].

The Endocrine Society's 2019 guideline stated: "We recommend against the use of GH or GH secretagogues for age-related physiologic GH decline in otherwise healthy adults because evidence for net benefit is insufficient and adverse effects are a concern." [3] This remains the prevailing guideline position as of 2025.

Interactions With Common Geriatric Medications

Several drug classes used heavily in older adults interact pharmacodynamically with tesamorelin.

Glucocorticoids

Systemic glucocorticoids suppress endogenous GHRH pulsatility and attenuate the pituitary response to exogenous GHRH analogues. Patients on prednisone above 5 mg/day or equivalent may show blunted IGF-1 responses and require dose reassessment [1].

Thyroid Hormone Replacement

Adequate thyroid hormone is necessary for normal GH-axis function. Subclinical hypothyroidism, common in older adults, should be treated before initiating tesamorelin because untreated hypothyroidism suppresses IGF-1 generation even when GH secretion is adequate [3].

Insulin and Oral Hypoglycemics

Because tesamorelin reduces insulin sensitivity, patients on sulfonylureas or insulin may need dose adjustments. Close glucose monitoring in the first 4 to 8 weeks of tesamorelin therapy is especially important in this subgroup [10].

Practical Administration Notes for Older Patients

Tesamorelin (Egrifta SV) comes as a lyophilized powder requiring reconstitution with the supplied sterile water. The injection technique demands modest manual dexterity. Older adults with arthritis, visual impairment, or tremor may need caregiver assistance or pharmacy-level pre-filling services. The drug must be refrigerated (2 to 8°C) and used within 3 hours of reconstitution [1].

Evening dosing (approximately 30 to 60 minutes before sleep) mimics endogenous nocturnal GH pulsatility and is preferred by most practitioners using this agent off-label in older patients, though the prescribing information specifies once-daily administration without a required time of day [1].

Cognitive Effects: The Most Cited Off-Label Rationale After Visceral Fat

The Baker et al. 2021 trial [7] generated substantial interest because cognitive improvement, not just body composition, was a primary endpoint. The executive-function signal, measured by the Trail Making Test and the Digit Symbol Coding test, was statistically significant at 20 weeks. Working memory improvements trended in the same direction without reaching significance.

How GH-axis stimulation might affect cognition is not fully understood. IGF-1 receptors are present throughout the central nervous system, particularly in hippocampal and prefrontal regions associated with memory and executive function [12]. Animal data show that IGF-1 promotes neurogenesis and synaptic plasticity, and that low IGF-1 accelerates amyloid accumulation in rodent Alzheimer's models [12]. Whether these mechanisms translate to clinically meaningful cognitive preservation in humans over years rather than weeks remains unknown.

A follow-on phase 3 trial (NCT04641598) targeting 228 participants with MCI aged 55 to 89 was registered in 2020 with a primary completion date of late 2024. Results had not been published in peer-reviewed form as of the publication date of this article. That trial will be the most important single data point for clinicians considering tesamorelin for cognitive indications in older adults.